Cue Biopharma (CUE NASDAQ) stock market data APIs
$28.5936
-0.18(-0.6%)
as of September 11, 2026
Try our APIs with
free plan!
Cue Biopharma Financial Data Overview
Price chart is built with
Anychart
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Prev. Close
28.5936
Open
28.4134
High
28.9064
Low
27.493
52 wk Range
4.971-45.5
Market Cap
209 M
Shares Outstanding
7 264 K
Revenue
37 655 K
EPS
-13.81
Beta
2.459
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cue Biopharma (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cue Biopharma data using free add-ons & libraries
Get Cue Biopharma Fundamental Data
Cue Biopharma Fundamental data includes:
- Net Revenue: 37 655 K
- EBITDA: -97 284 000
- Earnings Per Share: -29
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -1.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cue Biopharma News
New
Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M
* Cue Biopharma press release [https://seekingalpha.com/pr/20620099-cue-biopharma-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (CUE [https://seekingalpha.com/symbol/...
Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress
(RTTNews) - Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, announced the appointment of James Ahlers as Chief Financial Office...
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
It can be hard to identify which small-cap biotech stocks will end up in the vast sea of failed trials, and which have the makings of something more viable. The screener behind this article is built t...
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
DelveInsight Business Research LLP The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing a...
Get Cue Biopharma fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
